Literature DB >> 20370674

Role of microRNAs in non-alcoholic steatohepatitis.

Onpan Cheung1, Arun J Sanyal.   

Abstract

The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is not entirely understood. Recently, the role of microRNA in this liver disease entity and its implication in disease pathogenesis and therapeutic potential has advanced rapidly over the year. While the regulation of miRNA function and its mechanism of actions on translational control of target mRNA expression remain unknown, advances in miRNA research allow identification and biochemical characterization of events that limit protein expression, which is crucial in various forms of human diseases and their subsequent development. It is hoped that further understanding of the role of microRNA in NAFLD will advance potential therapeutics and preventive measures to modify and alter this disease process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20370674     DOI: 10.2174/138161210791208866

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  14 in total

Review 1.  microRNAs: fad or future of liver disease.

Authors:  Ashley M Lakner; Herbert L Bonkovsky; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

Review 2.  New insights from rodent models of fatty liver disease.

Authors:  Jacquelyn J Maher
Journal:  Antioxid Redox Signal       Date:  2011-04-26       Impact factor: 8.401

Review 3.  Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.

Authors:  Yu-Yuan Li
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

Review 4.  MicroRNA silencing and the development of novel therapies for liver disease.

Authors:  Gyongyi Szabo; Peter Sarnow; Shashi Bala
Journal:  J Hepatol       Date:  2012-04-12       Impact factor: 25.083

5.  Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis.

Authors:  Diptadip Dattaroy; Sahar Pourhoseini; Suvarthi Das; Firas Alhasson; Ratanesh Kumar Seth; Mitzi Nagarkatti; Gregory A Michelotti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-12-11       Impact factor: 4.052

6.  The effect of miRNA-122 in regulating fat deposition in a cell line model.

Authors:  Yu-Qiang Nie; Jie Cao; Yong-Jian Zhou; Xia Liang; Yan-Lei Du; Yu-Jui Yvonne Wan; Yu-Yuan Li
Journal:  J Cell Biochem       Date:  2014-05       Impact factor: 4.429

Review 7.  MicroRNAs and atherosclerosis.

Authors:  Julio Madrigal-Matute; Noemi Rotllan; Juan F Aranda; Carlos Fernández-Hernando
Journal:  Curr Atheroscler Rep       Date:  2013-05       Impact factor: 5.113

8.  Upregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis.

Authors:  Sahar Pourhoseini; Ratanesh Kumar Seth; Suvarthi Das; Diptadip Dattaroy; Maria B Kadiiska; Guanhua Xie; Gregory A Michelotti; Mitzi Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

9.  A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism.

Authors:  Yang Xu; Munaf Zalzala; Jiesi Xu; Yuanyuan Li; Liya Yin; Yanqiao Zhang
Journal:  Nat Commun       Date:  2015-06-23       Impact factor: 14.919

Review 10.  MicroRNA function in the profibrogenic interplay upon chronic liver disease.

Authors:  Jia Huang; Xiaojie Yu; Jochen W U Fries; Li'ang Zhang; Margarete Odenthal
Journal:  Int J Mol Sci       Date:  2014-05-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.